

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lisa Gray
Date of last notice	4 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	2 January 2020
No. of securities held prior to change	
Class	A. Fully paid ordinary shares B. Class A performance rights C. Class B performance rights
Number acquired	A. 16,413,065 B. 52,391,228 C. 52,391,228
Number disposed	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A. Issued at \$0.055 per share for nil cash consideration as consideration shares to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. B. Issued at nil cash consideration as consideration rights to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 4 of the Notice of Annual General Meeting dated 25 October 2019. C. Issued at nil cash consideration as consideration rights to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 5 of the Notice of Annual General Meeting dated 25 October 2019.
No. of securities held after change	16,413,065 ordinary shares 52,391,228 Class A performance rights 52,391,228 Class B performance rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. As approved by shareholders on 28 November 2019 B. As approved by shareholders on 28 November 2019 C. As approved by shareholders on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Osagie Imasogie
Date of last notice	4 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	2 January 2020
No. of securities held prior to change	
Class	A. Fully paid ordinary shares B. Class A performance rights C. Class B performance rights
Number acquired	A. 16,413,065 B. 52,391,228 C. 52,391,228
Number disposed	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A. Issued at \$0.055 per share for nil cash consideration as consideration shares to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. B. Issued at nil cash consideration as consideration rights to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 4 of the Notice of Annual General Meeting dated 25 October 2019. C. Issued at nil cash consideration as consideration rights to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 5 of the Notice of Annual General Meeting dated 25 October 2019.
No. of securities held after change	16,413,065 ordinary shares 52,391,228 Class A performance rights 52,391,228 Class B performance rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. As approved by shareholders on 28 November 2019 B. As approved by shareholders on 28 November 2019 C. As approved by shareholders on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oludare Odumosu
Date of last notice	4 December 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	2 January 2020
No. of securities held prior to change	
Class	A. Fully paid ordinary shares B. Class A performance rights C. Class B performance rights
Number acquired	A. 5,500,655 B. 17,558,328 C. 17,558,328
Number disposed	

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	A. Issued at \$0.055 per share for nil cash consideration as consideration shares to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. B. Issued at nil cash consideration as consideration rights to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 4 of the Notice of Annual General Meeting dated 25 October 2019. C. Issued at nil cash consideration as consideration rights to the Ilera Therapeutics vendors as approved by shareholders at the 2019 Annual General Meeting. The terms and conditions of the Performance Rights are details in Schedule 5 of the Notice of Annual General Meeting dated 25 October 2019.
No. of securities held after change	5,500,655 ordinary shares 17,558,328 Class A performance rights 17,558,328 Class B performance rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	A. As approved by shareholders on 28 November 2019 B. As approved by shareholders on 28 November 2019 C. As approved by shareholders on 28 November 2019

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.